![](/img/cover-not-exists.png)
A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis
Allanore, Yannick, Wung, Peter, Soubrane, Christina, Esperet, Corinne, Marrache, Frederic, Bejuit, Raphael, Lahmar, Amel, Khanna, Dinesh, Denton, Christopher PJournal:
Annals of the Rheumatic Diseases
DOI:
10.1136/annrheumdis-2020-218447
Date:
September, 2020
File:
PDF, 1002 KB
2020